Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.
Also called NCT01478971
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 184 participants
- Sponsor
- Registry
-
NCT01478971 -
U1111-1150-2575
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01478971. Allocation not applicable; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
- Acronym
- DIAMOND
- Condition
- Chronic Kidney Disease
- Condition
- Anemia
- Intervention (Drug)
- Epoetin
- Intervention (Drug)
- Peginesatide
- Lead sponsor
- Takeda
- Collaborator
- Affymax
Record details
- Record id
cardio:ct-nct01478971- Content hash
8f6dbc2088d43847404e78969f7a34f9a213cfb9fa9ad2680a92e223ddf8a2ff